Search

Displaying results 5991 - 6000 of 10000 in total
  1. Drug

    (4R)-limonene

    go.drugbank.com/drugs/DB08921
    Investigational

    As the main odor constituent of citrus (plant family Rutaceae), D-limonene is used in food manufacturing and some medicines, e.g. as a flavoring to mask the bitter taste of alkaloids, and as a fragrant

  2. Drug

    Gavocabtagene autoleucel

    go.drugbank.com/drugs/DB17367
    Investigational

    which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. … Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit

  3. Drug

    Farletuzumab ecteribulin

    go.drugbank.com/drugs/DB18857
    Investigational

    Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), … a Folate Receptor Alpha (Frα)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).

  4. Drug

    Acepromazine

    go.drugbank.com/drugs/DB01614
    InvestigationalVet approved

    Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.

    Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor Antagonists
  5. Drug

    N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide

    go.drugbank.com/drugs/DB08559
    Experimental

    This compound belongs to the penicillins. … from the sulfur atom at position 1].

  6. Drug

    TMC-310911

    go.drugbank.com/drugs/DB15623
    Investigational

    TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir]. … TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for

  7. Drug

    Thienylfentanyl

    go.drugbank.com/drugs/DB09180
    ExperimentalIllicit

    Thienylfentanyl is a fentanyl analog analgesic that was sold on the black market in the 1980s until the Federal Analog Act scheduled drugs based on structural similarity rather than scheduling drugs individually … Thienylfentanyl has a similar synthesis pathway to fentanyl except 2-(2-bromoethyl)thiophene is substituted for phenethyl bromide.

  8. Drug

    (3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol

    go.drugbank.com/drugs/DB06943
    Experimental

    This compound belongs to the benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. … This substance is known to target disintegrin and metalloproteinase domain-containing protein 17.

  9. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. … Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited

  10. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    The drug was also evaluated in the treatment of retinal detachment and other diseases of the retina. Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.